Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular IG-LIKE DOMAINS which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
| Descriptor ID |
D040262
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950 D12.776.543.750.630.750 D12.776.543.750.750.400.910
|
| Concept/Terms |
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Endothelial Cell Growth Factor
- Receptor, Vascular Permeability Factor
- VEGF Receptors
- Receptors, VEGF
- Vascular Endothelial Cell Growth Factor Receptor
- VPF Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- Vascular Permeability Factor Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in this website by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 2 | 4 |
| 2010 | 2 | 3 | 5 |
| 2011 | 0 | 4 | 4 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 5 | 5 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 3 | 4 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration. Sci Rep. 2024 06 26; 14(1):14752.
-
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 23; 403(10432):1141-1152.
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.
-
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials. Pharmaceut Med. 2024 Jan; 38(1):63-73.
-
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 Dec 01; 141(12):1152-1160.
-
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
-
Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data. Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01; 12(2):168-183.
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
-
Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biol Psychiatry. 2022 01 01; 91(1):102-117.